Latest From Affibody AB
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Leading US biotech Alexion is to collaborate with two European biotechs, Affibody and Zealand, on early-stage products for rare diseases, involving bivalent antibody-mimetic scaffolds and novel peptides.
Alexion’s third deal this year brings privately held Syntimmune and its Phase Ib/IIa candidate for three IgG-mediated rare disorders, including warm autoimmune hemolytic anemia, for a $400m upfront price tag.
David Bejker, CEO of Affibody, a Swedish biotech developing a novel psoriasis product, talks to Scrip's Lucie Ellis about the company's recently launched Phase II trial.
- Large Molecule
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Affibody AB
- Senior Management
David Bejker, CEO
Johan Stuart, CFO
Fredrik Frejd, PhD, CSO
- Contact Info
Phone: (46) 8 59 88 38 00
Gunnar Asplunds Allé 24
Solna, SE-171 63
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.